Karakousis C P, Douglass H O, Yeracaris P M, Holyoke E D
Arch Surg. 1976 Jun;111(6):716-8. doi: 10.1001/archsurg.1976.01360240096018.
Twenty-one patients with malignant melanoma received immunotherapy with BCG. Thirteen patients had adjuvant immunotherapy on a monthly schedule. Of these, eight with regional lymph node metastases (stage III) had been treated by lymphadenectomy. Two of the stage III patients had tumor recurrences within one year, while six are alive and free of melanoma at a median interval of 22 months. The remaining five patients (stage I or II) had level 4 or 5 (Clark classification) primary lesions. Their average tumor-free survival has been 18 months, but there was one regional recurrence in six months. Eight patients received intralesional treatment with BCG. The extent of local response correlated inversely to the stage of their disease. Higher doses of BCG or multiple simultaneous injections into the same lesion did not produce complete resolution of nodules in patients with far-advanced melanoma. In none was the course altered by intralesional therapy.
21例恶性黑色素瘤患者接受了卡介苗免疫治疗。13例患者按每月一次的方案接受辅助免疫治疗。其中，8例有区域淋巴结转移（III期）的患者接受了淋巴结切除术。III期患者中有2例在一年内出现肿瘤复发，而6例存活且无黑色素瘤，中位间隔时间为22个月。其余5例患者（I期或II期）有4级或5级（克拉克分类法）原发性病变。他们的平均无瘤生存期为18个月，但有1例在6个月时出现区域复发。8例患者接受了卡介苗瘤内注射治疗。局部反应程度与疾病分期呈负相关。对于晚期黑色素瘤患者，更高剂量的卡介苗或在同一病变内同时多次注射并不能使结节完全消退。瘤内治疗均未改变病程。
